Elsevier

Vaccine

Volume 29, Issue 48, 8 November 2011, Pages 8767-8768
Vaccine

Meeting report
Rubella vaccines: WHO position paper—Recommendations

https://doi.org/10.1016/j.vaccine.2011.08.061Get rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (30)

  • Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial

    2022, The Lancet Global Health
    Citation Excerpt :

    Seroconversion was defined as a four-fold rise or more in antibody titre from day 0 to day 28 and from day 0 to day 730–1035 after vaccination. Seroprotection was defined in accordance with the WHO standard reference values of GMT of 120 mIU/mL for measles or higher and 10 IU/mL or higher for rubella.22,23 Study results were analysed using SAS software, version 9.4.

  • Adverse pregnancy outcomes among pregnant women with acute Rubella infections in Mwanza city, Tanzania

    2019, International Journal of Infectious Diseases
    Citation Excerpt :

    Additionally, the coverage of Measles first dose vaccine was around 80% with some regions reported below 80% (Semali, 2010). It should be noted that the main prerequisite, prior to the introduction of the Rubella vaccine, is to achieve a first dose Measles vaccine coverage of not lower than 80% (Publication, 2011). Introducing the Rubella vaccine when the Measles vaccine coverage is low may result into a shift of average age exposure due to the presence of non-immune individuals and eventually increase the prevalence of CRS.

  • Rubella Virus

    2018, Principles and Practice of Pediatric Infectious Diseases
  • Rubella

    2015, The Lancet
    Citation Excerpt :

    The plan includes a five-pronged strategy to: achieve and maintain high levels of population immunity with 95% or higher vaccination coverage with two doses of measles-containing and rubella-containing vaccines; monitor disease with effective surveillance and assess programmatic efforts; develop outbreak preparedness and respond rapidly to outbreaks; communicate and engage with the public to build confidence in and demand for immunisation; and undertake the research and development needed to support cost-effective operations and improve vaccination and diagnostic methods. In 2011, WHO updated its guidance on rubella-containing vaccine use with a clear recommendation that countries that have not yet introduced rubella-containing vaccines should take the opportunity of accelerated measles control and elimination activities to include rubella-containing vaccines in their immunisation programmes.47 Because all countries have elimination targets, their measles vaccine delivery strategies provide a platform to advance rubella and congenital rubella syndrome elimination through the use of combined vaccines (eg, measles–rubella vaccine [MR] or MMR).

  • Rubella susceptibility in pregnant women and results of a postpartum immunization strategy in Catalonia, Spain

    2015, Vaccine
    Citation Excerpt :

    Post-delivery vaccination strategies should include MMR vaccination in women susceptible to these diseases. In susceptible pregnant women, immunization with this live attenuated vaccine should be administrated during the postpartum period [2,9,10]. In Spain, rubella is a notifiable disease and is monitored through the Spanish Surveillance System [11].

View all citing articles on Scopus
View full text